Affordable Access

Publisher Website

In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and β-lactamase studies

Authors
Journal
Diagnostic Microbiology and Infectious Disease
0732-8893
Publisher
Elsevier
Publication Date
Volume
3
Issue
6
Identifiers
DOI: 10.1016/s0732-8893(85)80005-5
Disciplines
  • Biology

Abstract

Abstract Cefoperazone was tested against 554 clinical isolates alone and with sulbactam in three combinations. The addition of sulbactam in low concentrations (≤4 µg/ml) improved the spectrum of cefoperazone principally against gram-negative bacilli such as Acinetobacter species, some Pseudomonas species, and β-1actamase-positive Enterobacterioceae. Nearly all of the spectrum increase was achieved at a sulbactam level of ≤2 µg/ml. Sulbactam was found to be an effective antimicrobial agent agains Acinetobacter species (MIC 50, 1.0 µg/ml), Pseudomonas acidovorans (MIC 50, 2.0 µg/ml), Neisseria gonorrhoeoe (MIC 50, ≤0.5 µg/ml), and N. meningitidis (MIC 50, ≤0.5 µg/ml). Sulbactam had a higher affinity and binding constant for the plasmid-mediated β-lactamases such as TEM-1 and TEM-2 compared to cefoperazone (≥lO-fold difference). This finding was important as cefoperazone con be hydrolyzed at a moderate rate by the highly efficient TEM enzymes (<2% of clinical Escherichia coli isolates). Sulbactam increased the susceptibility (≤16 µg/ml) of 220 isolates of Enterobacteriaceoe to cefoperazone from 88.6 to 96.3% when 4.0 µg/ml of sulbactam was added. The cefoperazone antimicrobial activity was also increased against the nonenteric bacilli from a 69.5 to a 87.4% total inhibition. MICs among cefoperazone-susceptible gram-negative and gram-positive strains were rountinely decreased 2- to 32-fold, as calculated from MIC 90 results. Therefore, sulbactam should predictably increase the antimicrobial spectrum and clinical effectiveness of cefoperazone against nosocomial and other pathogens such as the plasmid-containing enteric bacilli, Bacteroides species and Acinetobacter species, and possibly provide the opportunity to reduce dosage schedules for infecting species already susceptible to cefoperazone alone.

There are no comments yet on this publication. Be the first to share your thoughts.